SANDOZ ATORVASTATIN TABLET

Страна: Канада

мова: англійська

Джерело: Health Canada

Активний інгредієнт:

ATORVASTATIN (ATORVASTATIN CALCIUM)

Доступна з:

SANDOZ CANADA INCORPORATED

Код атс:

C10AA05

ІПН (Міжнародна Ім'я):

ATORVASTATIN

Дозування:

10MG

Фармацевтична форма:

TABLET

Склад:

ATORVASTATIN (ATORVASTATIN CALCIUM) 10MG

Адміністрація маршрут:

ORAL

Одиниць в упаковці:

30/100/500

Тип рецепту:

Prescription

Терапевтична области:

HMG-COA REDUCTASE INHIBITORS

Огляд продуктів:

Active ingredient group (AIG) number: 0133055001; AHFS:

Статус Авторизація:

APPROVED

Дата Авторизація:

2010-05-19

Характеристики продукта

_Sandoz Atorvastatin _
_ _
_Page 1 of 63_
_ _
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
SANDOZ ATORVASTATIN
Atorvastatin Calcium Tablets
Tablets, 10 mg, 20 mg, 40 mg and 80 mg atorvastatin (as atorvastatin
calcium trihydrate), Oral
Manufacturer’s Standard
Lipid Metabolism Regulator
Sandoz Canada Inc.
110 Rue de Lauzon
Boucherville, Québec, Canada
J4B 1E6
Date of Initial Authorization:
May 19, 2010
Date of Revision:
September 11, 2023
Submission Control Number: 274576
_Sandoz Atorvastatin _
_ _
_Page 2 of 63_
_ _
RECENT MAJOR LABEL CHANGES
2 Contraindications
7 Warnings and Precautions, Musculoskeletal
09/2023
7 Warnings and Precautions, Musculoskeletal
09/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
....................................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
5
2
CONTRAINDICATIONS
......................................................................................................
5
4
DOSAGE AND ADMINISTRATION
......................................................................................
6
4.1
Dosing Considerations
...............................................................................................
6
4.2
Recommended Dose and Dosage Adjustment
.......................................................... 6
4.4